|
1
|
Hwang JA, Lee BB, Kim Y, Park SE, Heo K,
Hong SH, Kim YH, Han J, Shim YM, Lee YS and Kim DH: HOXA11
hypermethylation is associated with progression of non-small cell
lung cancer. Oncotarget. 4:2317–2325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calvayrac O, Pradines A, Pons E, Mazières
J and Guibert N: Molecular biomarkers for lung adenocarcinoma. Eur
Respir J. 49:16017342017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sholl LM: Biomarkers in lung
adenocarcinoma: A decade of progress. Arch Pathol Lab Med.
139:469–480. 2015. View Article : Google Scholar
|
|
4
|
Wallerek S and Sørensen JB: Biomarkers for
efficacy of adjuvant chemotherapy following complete resection in
NSCLC stages I-IIIA. Eur Respir Rev. 24:340–355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi L, Li Y, Qin Y, Shi G, Li T, Wang J,
Chen L, Gu Y, Zhao W and Guo Z: An individualised signature for
predicting response with concordant survival benefit for lung
adenocarcinoma patients receiving platinum-based chemotherapy. Br J
Cancer. 115:1513–1519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chalela R, Curull V, Enriquez C, Pijuan L,
Bellosillo B and Gea J: Lung adenocarcinoma: From molecular basis
to genome-guided therapy and immunotherapy. J Thorac Dis.
9:2142–2158. 2017. View Article : Google Scholar :
|
|
7
|
Wang L, Cui Y, Sheng J, Yang Y, Kuang G,
Fan Y, Jin J and Zhang Q: Epigenetic inactivation of HOXA11, a
novel functional tumor suppressor for renal cell carcinoma, is
associated with RCC TNM classification. Oncotarget. 8:21861–21870.
2017.PubMed/NCBI
|
|
8
|
Se YB, Kim SH, Kim JY, Kim JE, Dho YS, Kim
JW, Kim YH, Woo HG, Kim SH, Kang SH, et al: Underexpression of
HOXA11 is associated with treatment resistance and poor prognosis
in glioblastoma. Cancer Res Treat. 49:387–398. 2017. View Article : Google Scholar
|
|
9
|
Whitcomb BP, Mutch DG, Herzog TJ, Rader
JS, Gibb RK and Goodfellow PJ: Frequent HOXA11 and THBS2 promoter
methylation, and a methylator phenotype in endometrial
adenocarcinoma. Clin Cancer Res. 9:2277–2287. 2003.PubMed/NCBI
|
|
10
|
Speleman F, Cauwelier B, Dastugue N, Cools
J, Verhasselt B, Poppe B, Van Roy N, Vandesompele J, Graux C,
Uyttebroeck A, et al: A new recurrent inversion, inv(7)(p15q34),
leads to transcriptional activation of HOXA10 and HOXA11 in a
subset of T-cell acute lymphoblastic leukemias. Leukemia.
19:358–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia B, Shan M, Wang J, Zhong Z, Geng J, He
X, Vu T, Zhang D and Pang D: Homeobox A11 hypermethylation
indicates unfavorable prognosis in breast cancer. Oncotarget.
8:9794–9805. 2017.
|
|
12
|
Li Q, Chen C, Ren X and Sun W: DNA
methylation profiling identifies the HOXA11 gene as an early
diagnostic and prognostic molecular marker in human lung
adenocarcinoma. Oncotarget. 8:33100–33109. 2017.PubMed/NCBI
|
|
13
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Chen G, Kronenberger P, Teugels E, Umelo
IA and De Grève J: Targeting the epidermal growth factor receptor
in non-small cell lung cancer cells: The effect of combining RNA
interference with tyrosine kinase inhibitors or cetuximab. BMC Med.
10:282012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo YH, Tang W, Zhang X, Tan Z, Guo WL,
Zhao N, Pang SM, Dang YW, Rong MH and Cao J: Promising significance
of the association of miR-204 5p expression with
clinicopathological features of hepatocellular carcinoma. Medicine
(Baltimore). 96:e75452017. View Article : Google Scholar
|
|
17
|
Yang X, Pang YY, He RQ, Lin P, Cen JM,
Yang H, Ma J and Chen G: Diagnostic value of strand-specific
miRNA-101 3p and miRNA-101 5p for hepatocellular carcinoma and a
bioinformatic analysis of their possible mechanism of action. FEBS
Open Bio. 8:64–84. 2017. View Article : Google Scholar
|
|
18
|
Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia
W, Yi X and Liu M: MicroRNA-92a as a potential biomarker in
diagnosis of colorectal cancer: A systematic review and
meta-analysis. PLoS One. 9:e887452014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stearman RS, Dwyer-Nield L, Zerbe L,
Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT,
Franklin WA, et al: Analysis of orthologous gene expression between
human pulmonary adenocarcinoma and a carcinogen-induced murine
model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ,
Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH and Huang CY:
Selection of DDX5 as a novel internal control for Q-RT-PCR from
microarray data using a block bootstrap re-sampling scheme. BMC
Genomics. 8:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar
|
|
26
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocar-cinoma
and integration with mRNA expression. Genome Res. 22:1197–1211.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Javed S and Langley SE: Importance of HOX
genes in normal prostate gland formation, prostate cancer
development and its early detection. BJU Int. 113:535–540. 2014.
View Article : Google Scholar
|
|
29
|
Lopez-Romero R, Marrero-Rodriguez D,
Romero-Morelos P, Villegas V, Valdivia A, Arreola H, Huerta-Padilla
V and Salcedo M: The role of developmental HOX genes in cervical
cancer. Rev Med Inst Mex Seguro Soc. 53(Suppl 2): S188–S193.
2015.In Spanish.
|
|
30
|
Nelson HH, Marsit CJ, Christensen BC,
Houseman EA, Kontic M, Wiemels JL, Karagas MR, Wrensch MR, Zheng S,
Wiencke JK and Kelsey KT: Key epigenetic changes associated with
lung cancer development: Results from dense methylation array
profiling. Epigenetics. 7:559–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bibikova M, Lin Z, Zhou L, Chudin E,
Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, et al:
High-throughput DNA methylation profiling using universal bead
arrays. Genome Res. 16:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu W, Zhao S, Wang Y, Zhao BN, Zhao W and
Zhou X: Identification of cancer prognosis-associated functional
modules using differential co-expression networks. Oncotarget.
8:112928–112941. 2017. View Article : Google Scholar
|
|
33
|
Eke I and Cordes N: Focal adhesion
signaling and therapy resistance in cancer. Semin Cancer Biol.
31:65–75. 2015. View Article : Google Scholar
|
|
34
|
Liu QZ, Gao XH, Chang WJ, Gong HF, Fu CG,
Zhang W and Cao GW: Expression of ITGB1 predicts prognosis in
colorectal cancer: A large prospective study based on tissue
microarray. Int J Clin Exp Pathol. 8:12802–12810. 2015.
|
|
35
|
Oshita F, Kameda Y, Ikehara M, Tanaka G,
Yamada K, Nomura I, Noda K, Shotsu A, Fujita A, Arai H, et al:
Increased expression of integrin beta1 is a poor prognostic factor
in small-cell lung cancer. Anticancer Res. 22:1065–1070.
2002.PubMed/NCBI
|
|
36
|
Yao ES, Zhang H, Chen YY, Lee B, Chew K,
Moore D and Park C: Increased beta1 integrin is associated with
decreased survival in invasive breast cancer. Cancer Res.
67:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
|
